|
|
News Breaks | | | | November 12, 2012 | | 08:05 EDT |  | CHMT | Chemtura to sell Antioxidant and UV Stabilizers buiness for $200M to SK Capital
Chemtura announced it has entered into an asset purchase agreement to sell its Antioxidant and UV Stabilizers business, including dedicated manufacturing plants in the U.S, France, and Germany, to an affiliate of SK Capital Partners, for $200M and the assumption of certain liabilities. The purchase price is subject to a post-closing net working capital adjustment. The transaction is subject to customary closing conditions. Proceeds from the sale will be used for repayment of debt and investment in Chemtura’s continued growth. The transaction is expected to close by the end of 2012 or in early 2013. | |
|
News For CHMT From The Last 14 Days Check below for free stories on CHMT the last two weeks. |
|
|
| June 7, 2013 | | 10:11 EDT |  | CHMT | On The Fly: Analyst Downgrade Summary
 Subscribe for More Information | | | 07:32 EDT | | CHMT | Chemtura downgraded to Underperform from Perform at Oppenheimer
Subscribe for More Information | | | June 6, 2013 | | 18:40 EDT | | CHMT | Chemtura says Q2 tracking similar to Q1
Craig A. Rogerson, Chairman, President and CEO of Chemtura, commented: "With the first two months of the quarter behind us, we are seeing similar trends in performance to those we saw in the first quarter of 2013. Three of our four segments are performing well and are tracking to deliver comparable results to the second quarter of 2012. However, Industrial Engineered Products continues to face challenging business conditions. With the weakness in Industrial Engineered Products, we now project to fall short of our performance in the second quarter of 2012 on a continuing operations basis. We are encouraged that the performance of this segment appears to be 'bottoming' this quarter and anticipate improving results over the second half of 2013. We are encouraged by the robust performance of our other three segments. We are also on track to eliminate the stranded costs from the divestiture of our Antioxidants business." | |
|
|
|
|
|
|
